Advances in the treatment of metastatic melanoma have improved responses and survival.
However, many patients continue to experience resistance or toxicity to treatment …

Immunomodulatory drugs that leverages host immune mechanisms to destroy tumor cells
have been met with great promise in the treatment of cancer. Immunotherapy, targeting …

Gut bacteria modulate the response to immune checkpoint blockade (ICB) treatment in
cancer, but the effect of diet and supplements on this interaction is not well studied. We …

Abstract Treatment with immune checkpoint blockade (ICB) has revolutionized cancer
therapy. Until now, predictive biomarkers,,,,,,,,–and strategies to augment clinical response …

T cell–mediated immunotherapies are promising cancer treatments. However, most patients
still fail to respond to these therapies. The molecular determinants of immune resistance are …

Background Immune checkpoint therapy has dramatically changed the landscape of cancer
therapy, providing an efficacious and durable therapeutic option for patients with advanced …

Abstract Treatment with combined immune checkpoint blockade (CICB) targeting CTLA-4
and PD-1 is associated with clinical benefit across tumor types, but also a high rate of …

Immune checkpoint blockade represents a major breakthrough in cancer therapy; however,
responses are not universal. Genomic and immune features in pretreatment tumor biopsies …

Immune checkpoint blockade produces clinical benefit in many patients. However, better
biomarkers of response are still needed, and mechanisms of resistance remain incompletely …

Preclinical studies suggest that treatment with neoadjuvant immune checkpoint blockade is
associated with enhanced survival and antigen-specific T cell responses compared with …